Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by CHRISTOPHER J LOGOTHETIS and NORA M NAVONE.
CHRISTOPHER J LOGOTHETIS
Connection Strength
3.400
NORA M NAVONE
  1. Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series. Clin Cancer Res. 2024 Mar 15.
    View in: PubMed
    Score: 0.248
  2. Targeting prostate cancer bone metastases. Cancer. 2003 Feb 01; 97(3 Suppl):785-8.
    View in: PubMed
    Score: 0.230
  3. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. Clin Cancer Res. 2020 09 15; 26(18):4933-4946.
    View in: PubMed
    Score: 0.192
  4. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res. 2000 Mar; 6(3):1190-7.
    View in: PubMed
    Score: 0.188
  5. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Na?ve Metastatic Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):990-999.
    View in: PubMed
    Score: 0.186
  6. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol. 1999 Jan; 161(1):304-8.
    View in: PubMed
    Score: 0.173
  7. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2493-500.
    View in: PubMed
    Score: 0.161
  8. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med. 2014 Sep 03; 6(252):252ra122.
    View in: PubMed
    Score: 0.128
  9. Prioritizing genes associated with prostate cancer development. BMC Cancer. 2010 Nov 02; 10:599.
    View in: PubMed
    Score: 0.098
  10. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest. 2008 Aug; 118(8):2697-710.
    View in: PubMed
    Score: 0.084
  11. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res. 2008 Jun 15; 14(12):3729-36.
    View in: PubMed
    Score: 0.083
  12. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene. 2008 Sep 04; 27(39):5195-203.
    View in: PubMed
    Score: 0.083
  13. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res. 2008 Mar 15; 14(6):1599-602.
    View in: PubMed
    Score: 0.082
  14. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene. 2008 Jan 24; 27(5):596-603.
    View in: PubMed
    Score: 0.079
  15. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res. 2004 Sep-Oct; 24(5A):2897-903.
    View in: PubMed
    Score: 0.064
  16. Bone mimetic environments support engineering, propagation, and analysis of therapeutic response of patient-derived cells, ex vivo and in vivo. Acta Biomater. 2024 Apr 01; 178:83-92.
    View in: PubMed
    Score: 0.062
  17. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Res Commun. 2023 12 13; 3(12):2531-2543.
    View in: PubMed
    Score: 0.061
  18. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res. 2003 Jul; 9(7):2587-97.
    View in: PubMed
    Score: 0.059
  19. Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones. Prostate Cancer Prostatic Dis. 2023 Dec; 26(4):751-758.
    View in: PubMed
    Score: 0.056
  20. Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components. Cancers (Basel). 2022 Jun 30; 14(13).
    View in: PubMed
    Score: 0.055
  21. Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Rep. 2022 04 05; 39(1):110595.
    View in: PubMed
    Score: 0.054
  22. Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Cancer Lett. 2002 Feb 08; 176(1):57-63.
    View in: PubMed
    Score: 0.054
  23. Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts. Cancer Chemother Pharmacol. 2001 Oct; 48(4):319-26.
    View in: PubMed
    Score: 0.052
  24. Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel. Oncogene. 2021 11; 40(44):6284-6298.
    View in: PubMed
    Score: 0.052
  25. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res. 2001 Jul 15; 61(14):5652-9.
    View in: PubMed
    Score: 0.052
  26. Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clin Cancer Res. 2021 06 01; 27(11):3253-3264.
    View in: PubMed
    Score: 0.050
  27. Fibroblast growth factors signaling in bone metastasis. Endocr Relat Cancer. 2020 07; 27(7):R255-R265.
    View in: PubMed
    Score: 0.048
  28. Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer. Oncogene. 2019 06; 38(25):5038-5049.
    View in: PubMed
    Score: 0.044
  29. Engineered bone for probing organotypic growth and therapy response of prostate cancer tumoroids in vitro. Biomaterials. 2019 03; 197:296-304.
    View in: PubMed
    Score: 0.043
  30. Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone. Sci Transl Med. 2018 08 01; 10(452).
    View in: PubMed
    Score: 0.042
  31. Model systems of prostate cancer: uses and limitations. Cancer Metastasis Rev. 1998-1999; 17(4):361-71.
    View in: PubMed
    Score: 0.040
  32. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res. 2018 02 01; 24(3):696-707.
    View in: PubMed
    Score: 0.040
  33. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol. 1997 Feb; 157(2):569-74.
    View in: PubMed
    Score: 0.038
  34. Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer. Proc Natl Acad Sci U S A. 2016 Nov 08; 113(45):12786-12791.
    View in: PubMed
    Score: 0.037
  35. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. Neoplasia. 2016 Jan; 18(1):1-9.
    View in: PubMed
    Score: 0.035
  36. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc Natl Acad Sci U S A. 2015 Jul 07; 112(27):8403-8.
    View in: PubMed
    Score: 0.034
  37. Targeting the interleukin-11 receptor a in metastatic prostate cancer: A first-in-man study. Cancer. 2015 Jul 15; 121(14):2411-21.
    View in: PubMed
    Score: 0.033
  38. Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proc Natl Acad Sci U S A. 2015 Mar 24; 112(12):3776-81.
    View in: PubMed
    Score: 0.033
  39. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 2014 Mar 15; 74(6):1651-60.
    View in: PubMed
    Score: 0.031
  40. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate. 2012 Nov; 72(15):1638-47.
    View in: PubMed
    Score: 0.027
  41. Androgen regulation of 5a-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS One. 2011; 6(12):e28840.
    View in: PubMed
    Score: 0.027
  42. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res. 2012 Feb 01; 18(3):666-77.
    View in: PubMed
    Score: 0.027
  43. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011 Nov 30; 3(111):111ra121.
    View in: PubMed
    Score: 0.026
  44. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate. 2011 Jun 01; 71(8):846-56.
    View in: PubMed
    Score: 0.025
  45. Adipose tissue-derived stem cells promote prostate tumor growth. Prostate. 2010 Nov 01; 70(15):1709-15.
    View in: PubMed
    Score: 0.025
  46. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res. 2007 Jul 15; 67(14):6544-8.
    View in: PubMed
    Score: 0.020
  47. p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis. 2002 Aug; 23(8):1289-96.
    View in: PubMed
    Score: 0.014
  48. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res. 2002 Mar; 8(3):775-81.
    View in: PubMed
    Score: 0.013
  49. Structural alterations of chromosome 5 in twelve human prostate cancer cell lines. Cancer Genet Cytogenet. 1998 Oct 15; 106(2):105-9.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.